Format

Send to

Choose Destination
World J Surg Oncol. 2018 Apr 26;16(1):87. doi: 10.1186/s12957-018-1389-3.

Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients.

Author information

1
Department of Surgery, Division of Surgical Oncology, University of California, San Diego, Moores Cancer Center, 3855 Health Sciences Dr. Mail Code 0987, La Jolla, CA, 92093, USA.
2
Department of Surgery, Division of Surgical Oncology, University of California, San Diego, Moores Cancer Center, 3855 Health Sciences Dr. Mail Code 0987, La Jolla, CA, 92093, USA. k6kelly@ucsd.edu.

Abstract

BACKGROUND:

Patient selection for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is critically important to optimizing outcomes. There is currently no literature regarding the safety of CRS/HIPEC in patients with cirrhosis. The aim of this case series is to report the outcomes of three patients with well-compensated cirrhosis who underwent CRS/HIPEC.

METHODS:

Patients were identified from a prospectively maintained peritoneal surface malignancy database. Patient, tumor, and operative-related details were recorded as short-term postoperative outcomes. Results were analyzed using descriptive statistics.

RESULTS:

All patients had well-compensated (Child-Pugh Class A) cirrhosis and Eastern Cooperative Oncology Group (ECOG) performance status of 0. One patient had preoperative evidence of portal hypertension. All safely underwent CRS/HIPEC with completeness of cytoreduction (CC) scores of 0. The postoperative morbidity profile was unique, but all complications were manageable and resulted in full recovery to preoperative baseline status.

CONCLUSIONS:

Patient selection for CRS/HIPEC is critical for optimization of short- and long-term outcomes. This small series suggests that well-compensated cirrhosis should not be an absolute contraindication to CRS/HIPEC.

KEYWORDS:

Cirrhosis; Cytoreduction; Cytoreductive surgery; HIPEC

PMID:
29699564
PMCID:
PMC5922306
DOI:
10.1186/s12957-018-1389-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center